RenovoRx EBITDA vs. Short Ratio

RNXT Stock  USD 1.25  0.03  2.34%   
Based on the key profitability measurements obtained from RenovoRx's financial statements, RenovoRx may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess RenovoRx's ability to earn profits and add value for shareholders.
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-11.4 M
Current Value
-10.8 M
Quarterly Volatility
2.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, RenovoRx's ROIC is comparatively stable compared to the past year. ROE is likely to gain to 3.58 in 2024, whereas Free Cash Flow Yield is likely to drop (0.46) in 2024.
For RenovoRx profitability analysis, we use financial ratios and fundamental drivers that measure the ability of RenovoRx to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well RenovoRx utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between RenovoRx's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of RenovoRx over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
For more information on how to buy RenovoRx Stock please use our How to Invest in RenovoRx guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of RenovoRx. If investors know RenovoRx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about RenovoRx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.58)
Return On Assets
(0.70)
Return On Equity
(1.55)
The market value of RenovoRx is measured differently than its book value, which is the value of RenovoRx that is recorded on the company's balance sheet. Investors also form their own opinion of RenovoRx's value that differs from its market value or its book value, called intrinsic value, which is RenovoRx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because RenovoRx's market value can be influenced by many factors that don't directly affect RenovoRx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between RenovoRx's value and its price as these two are different measures arrived at by different means. Investors typically determine if RenovoRx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, RenovoRx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

RenovoRx Short Ratio vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining RenovoRx's current stock value. Our valuation model uses many indicators to compare RenovoRx value to that of its competitors to determine the firm's financial worth.
RenovoRx is rated fifth in ebitda category among its peers. It is rated second in short ratio category among its peers . At this time, RenovoRx's EBITDA is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value RenovoRx by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

RenovoRx Short Ratio vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

RenovoRx

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(11.4 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.

RenovoRx

Short Ratio

 = 

Short Interest

Average Trading Volume

 = 
3.43 X
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.

RenovoRx Short Ratio Comparison

RenovoRx is currently under evaluation in short ratio category among its peers.

RenovoRx Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in RenovoRx, profitability is also one of the essential criteria for including it into their portfolios because, without profit, RenovoRx will eventually generate negative long term returns. The profitability progress is the general direction of RenovoRx's change in net profit over the period of time. It can combine multiple indicators of RenovoRx, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive IncomeM3.1 M
Net Interest Income111 K116.5 K
Interest Income111 K64.3 K
Operating Income-11.4 M-10.8 M
Net Loss-9.2 M-9.6 M
Income Before Tax-10.2 M-10.7 M
Total Other Income Expense Net1.2 M1.2 M
Net Loss-8.9 M-9.3 M
Net Loss-10.2 M-10.7 M
Income Tax Expense(6.00)(5.70)
Change To Netincome-29.7 K-28.2 K
Net Loss(0.99)(1.04)
Income Quality 1.00  0.74 
Net Income Per E B T 1.14  1.17 

RenovoRx Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on RenovoRx. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of RenovoRx position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the RenovoRx's important profitability drivers and their relationship over time.

Use RenovoRx in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if RenovoRx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in RenovoRx will appreciate offsetting losses from the drop in the long position's value.

RenovoRx Pair Trading

RenovoRx Pair Trading Analysis

The ability to find closely correlated positions to RenovoRx could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace RenovoRx when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back RenovoRx - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling RenovoRx to buy it.
The correlation of RenovoRx is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as RenovoRx moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if RenovoRx moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for RenovoRx can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your RenovoRx position

In addition to having RenovoRx in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Obamacare Repeal Thematic Idea Now

Obamacare Repeal
Obamacare Repeal Theme
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Repeal Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for RenovoRx Stock Analysis

When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.